Post-marketing surveillance of DIACOMITCapsule, Powder for Oral Suspensio
Not Applicable
Completed
- Conditions
- Dravet Syndrome
- Registration Number
- JPRN-jRCT1080225085
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
All patients who start receiving DIACOMIT Tablet during the registration period.
Exclusion Criteria
Patients with a previous history of hypersensitivity to the ingredients of DIACOMIT.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety<br>Information about the adverse events that have occurred, by adverse reaction/infection category. <br>Information about the safety specifications concerns that have occurred.
- Secondary Outcome Measures
Name Time Method efficacy<br>General improvement<br>Responder rate